Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 2
2018 5
2019 6
2020 6
2021 4
2022 2
2023 5
2024 4
2025 5
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators. Nissen SE, et al. N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4. N Engl J Med. 2023. PMID: 36876740 Clinical Trial.
The primary end point was a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization. ...CONCLUSIONS: Among statin-intolerant patients …
The primary end point was a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular …
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415628 Clinical Trial.
The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or no …
The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revasculariz …
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. Mach F, et al. Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455. Eur Heart J. 2020. PMID: 31504418 Free article. No abstract available.
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.
Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, Delgado V, Fabin N, Ference BA, Graham IM, Landmesser U, Laufs U, Mihaylova B, Nordestgaard BG, Richter DJ, Sabatine MS; ESC/EAS Scientific Document Group. Mach F, et al. Eur Heart J. 2025 Nov 7;46(42):4359-4378. doi: 10.1093/eurheartj/ehaf190. Eur Heart J. 2025. PMID: 40878289 Free article. No abstract available.
2025 ESC Guidelines for the management of cardiovascular disease and pregnancy.
De Backer J, Haugaa KH, Hasselberg NE, de Hosson M, Brida M, Castelletti S, Cauldwell M, Cerbai E, Crotti L, de Groot NMS, Estensen ME, Goossens ES, Haring B, Kurpas D, McEniery CM, Peters SAE, Rakisheva A, Sambola A, Schlager O, Schoenhoff FS, Simoncini T, Steinbach F, Sudano I, Swan L, Valente AM; ESC Scientific Document Group. De Backer J, et al. Eur Heart J. 2025 Nov 14;46(43):4462-4568. doi: 10.1093/eurheartj/ehaf193. Eur Heart J. 2025. PMID: 40878294 Free article. No abstract available.
Evinacumab for Homozygous Familial Hypercholesterolemia.
Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, Ali S, Banerjee P, Chan KC, Gipe DA, Khilla N, Pordy R, Weinreich DM, Yancopoulos GD, Zhang Y, Gaudet D; ELIPSE HoFH Investigators. Raal FJ, et al. N Engl J Med. 2020 Aug 20;383(8):711-720. doi: 10.1056/NEJMoa2004215. N Engl J Med. 2020. PMID: 32813947 Clinical Trial.
BACKGROUND: Homozygous familial hypercholesterolemia is characterized by premature cardiovascular disease caused by markedly elevated levels of low-density lipoprotein (LDL) cholesterol. ...Loss-of-function variants in the gene encoding angiopoietin-like 3 (ANGPTL3) are as …
BACKGROUND: Homozygous familial hypercholesterolemia is characterized by premature cardiovascular disease caused by markedly elevated …
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.
Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C, Fauchier L, Halle M, Herrington WG, Kautzky-Willer A, Lambrinou E, Lesiak M, Lettino M, McGuire DK, Mullens W, Rocca B, Sattar N; ESC Scientific Document Group. Marx N, et al. Eur Heart J. 2023 Oct 14;44(39):4043-4140. doi: 10.1093/eurheartj/ehad192. Eur Heart J. 2023. PMID: 37622663 Free article. No abstract available.
2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP).
Banach M, Reiner Ž, Surma S, Bajraktari G, Bielecka-Dabrowa A, Bunc M, Bytyçi I, Ceska R, Cicero AFG, Dudek D, Dyrbuś K, Fedacko J, Fras Z, Gaita D, Gavish D, Gierlotka M, Gil R, Gouni-Berthold I, Jankowski P, Járai Z, Jóźwiak J, Katsiki N, Latkovskis G, Magda SL, Margetic E, Margoczy R, Mitchenko O, Durak-Nalbantic A, Ostadal P, Paragh G, Petrulioniene Z, Paneni F, Pećin I, Pella D, Postadzhiyan A, Stoian AP, Trbusic M, Udroiu CA, Viigimaa M, Vinereanu D, Vlachopoulos C, Vrablik M, Vulic D, Penson PE; International Lipid Expert Panel (ILEP). Banach M, et al. Among authors: mitchenko o. Drugs. 2024 Dec;84(12):1541-1577. doi: 10.1007/s40265-024-02105-5. Epub 2024 Nov 4. Drugs. 2024. PMID: 39497020 Free PMC article.
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. ...In addition to statins, which have been available for several decades, ezetimibe, bempedoic acid (also as …
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidit …
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.
Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, Iung B, Johnson MR, Kintscher U, Kranke P, Lang IM, Morais J, Pieper PG, Presbitero P, Price S, Rosano GMC, Seeland U, Simoncini T, Swan L, Warnes CA; ESC Scientific Document Group. Regitz-Zagrosek V, et al. Eur Heart J. 2018 Sep 7;39(34):3165-3241. doi: 10.1093/eurheartj/ehy340. Eur Heart J. 2018. PMID: 30165544 Free article. No abstract available.
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
Marston NA, Bohula EA, Bhatia AK, De Ferrari GM, Leiter LA, Nicolau JC, Park JG, Murphy SA, Walsh E, Liu L, Verma S, Sattar N, Nicholls SJ, Lopez-Sendon J, Gouni-Berthold I, Tokgozoglu L, Blankstein R, Cyrille M, da Silva Lima GP, Giugliano RP, Sabatine MS; VESALIUS-CV Investigators. Marston NA, et al. JAMA. 2026 Apr 28;335(16):1400-1407. doi: 10.1001/jama.2026.3277. JAMA. 2026. PMID: 41903215 Clinical Trial.
IMPORTANCE: Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors for cardiovascular event reduction has largely been reserved for patients with significant atherosclerosis. ...CONCLUS …
IMPORTANCE: Intensive lowering of low-density lipoprotein cholesterol (LDL-C) levels with PCSK9 (proprotein convertase subtilisin/kexin type …
39 results